Related Experiment Video

Updated: Sep 13, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Myeloid-Derived Growth Factor-Regulated Oncogenesis in Lung Adenocarcinoma Is Associated with EGFR Status and Cancer

Ting-Feng Hsiao1,2, Chih-Liang Wang3,4, Yi-Cheng Wu5

  • 1Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.

Journal of Proteome Research
|August 2, 2025
PubMed

Insights

Myeloid-derived growth factor (MYDGF) shows promise as a biomarker for early-stage, wild-type epidermal growth factor receptor (EGFR) lung adenocarcinoma. Elevated MYDGF levels correlate with cancer stage and prognosis in these specific patients.

Area of Science:

  • Oncology
  • Proteomics
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are effective for EGFR-mutant lung adenocarcinoma (LUAD).
  • Effective treatment strategies for EGFR wild-type (WT) LUAD are still needed.
  • Identifying stage-specific biomarkers is crucial for personalized LUAD treatment.

Purpose of the Study:

  • To identify novel stage-specific biomarkers in EGFR-WT LUAD.
  • To investigate the role of myeloid-derived growth factor (MYDGF) in LUAD.
  • To understand the context-dependent functions of MYDGF based on EGFR status and cellular localization.

Main Methods:

  • Quantitative proteomics and multiomics analysis of LUAD patient cohorts.
  • Analysis of tissue and serum MYDGF levels in relation to EGFR mutation status and cancer stage.
  • Functional studies including MYDGF knockdown and proteomic analysis to assess its role in cell viability and migration.

Main Results:

  • Discovery of 21 dysregulated proteins in early-stage EGFR-WT LUAD.
  • Identification of MYDGF as a key candidate biomarker.
  • Elevated MYDGF levels in tissue and serum correlated with cancer stage in EGFR-WT LUAD.
  • A higher tumor-to-normal MYDGF ratio predicted a favorable prognosis in early-stage EGFR-WT LUAD.
  • MYDGF demonstrated context-dependent roles in cell viability and migration based on localization and cancer cell invasiveness.

Conclusions:

  • EGFR status and cancer stage define distinct proteomic profiles in LUAD.
  • MYDGF is a promising prognostic and diagnostic biomarker for EGFR-WT LUAD.
  • Understanding the context-dependent functions of MYDGF is essential for developing targeted therapies.
Keywords:
biomarkerlung adenocarcinomamyeloid-derived growth factorquantitative proteomicswild-type EGFR

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K